
    
      Portal vein thrombosis is not an uncommon complication in cirrhotic portal hypertension,
      which lead to a poor prognosis in endoscopic management of variceal bleeding. Evidence
      indicated that enoxaparin prevented PVT and liver decompensation via decreased rates of
      bacterial infections and lowered the potent inflammatory mediators such as interleukin-6.
      Rifaximin is a broad-spectrum antibiotic that exerts endotoxin-lowering and anti-inflammatory
      effects.
    
  